Supplementary Figure S5: Forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with overall survival on the capecitabine arm vs. observation. Expression status was derived from the median gene expression scores. Hazard ratios, 95% confidence intervals and *P*-values are derived from Cox regression analyses adjusted for age, menopausal status, histological grade, tumor size, stage, breast surgery, region, nodal status, and chemotherapy regimen. The displayed *P*-interaction indicates results of test of heterogeneity. Results for the remaining tested genes are presented in Figure 4.

Supplementary Figure S5

Subgroup	HR, 95%CI	P.value	P.interaction
Cytotoxic cells			0.94
High	0.69 (0.36–1.31)	0.25	
Low	0.87 (0.52–1.48)	0.61	
Mast cells			0.27
High	0.67 (0.39–1.16)	0.15	
Low	1.12 (0.61–2.02)	0.72	
Endothelial			0.5
High	0.96 (0.56–1.65)	0.88	
Low	0.72 (0.4–1.33)	0.29	
IL24			0.36
High	1.05 (0.59–1.86)	0.87	
Low	0.69 (0.4–1.21)	0.2	
IL22RA2			0.94
High	0.89 (0.49–1.63)	0.71	
Low	0.82 (0.48–1.39)	0.45	
NRCAM			0.64
High	0.93 (0.53–1.64)	0.81	
Low	0.72 (0.4–1.29)	0.27	
GRIA3			0.35
High	0.97 (0.55–1.71)	0.92	
Low	0.65 (0.37–1.16)	0.14	
SOCS3			0.79
High	0.64 (0.35–1.17)	0.15	
Low	0.88 (0.51–1.53)	0.65	
CXCL5			0.04
High	1.35 (0.77–2.38)	0.29	
Low	0.53 (0.3–0.95)	0.03	
VIT			0.54
High	0.96 (0.55–1.66)	0.88	
Low	0.69 (0.38–1.26)	0.22	
MME			0.18
High	1.18 (0.66–2.11)	0.59	
Low	0.62 (0.36–1.09)	0.09	
PLCB1			0.73
High	0.9 (0.54–1.52)	0.7	
Low	0.75 (0.4–1.4)	0.36	
SLC28A1			0.27
High	0.57 (0.3–1.07)	0.08	
Low	1.02 (0.59–1.75)	0.95	
CTSW			0.84
High	0.73 (0.4–1.36)	0.32	
Low	0.86 (0.5–1.49)	0.59	
CES1			0.8
High	0.79 (0.45–1.37)	0.4	
Low	0.97 (0.53–1.8)	0.93	
BMP2			0.78
High	0.89 (0.51–1.56)	0.69	
Low	0.72 (0.41–1.28)	0.26	
GZMH			0.43
High	0.71 (0.39–1.29)	0.25	
Low	0.99 (0.57–1.72)	0.98	
TGFB2			0.75
High	0.96 (0.54–1.71)	0.88	
Low	0.76 (0.44–1.33)	0.34	
HAS1			0.7
High	0.79 (0.45–1.38)	0.4	
Low	0.9 (0.5–1.61)	0.71	

Subgroup	HR, 95%CI	P.value	P.interaction
CCNA1			0.87
High	0.79 (0.46–1.37)	0.41	
Low	0.91 (0.51–1.64)	0.76	
CXCL10			0.54
High	0.66 (0.34–1.28)	0.21	
Low	0.92 (0.55–1.54)	0.76	
IL6			0.73
High	0.73 (0.41–1.28)	0.27	
Low	0.98 (0.55–1.73)	0.94	
CACNA2D3			0.4
High	1.05 (0.57–1.93)	0.87	
Low	0.68 (0.4–1.17)	0.16	
JAK1			0.19
High	0.56 (0.3–1.06)	0.07	
Low	1.11 (0.64–1.94)	0.7	
HOXA9			0.92
High	0.87 (0.5–1.54)	0.64	
Low	0.85 (0.46–1.55)	0.59	
TWIST2			0.82
High	0.83 (0.47–1.45)	0.51	
Low	0.79 (0.44–1.41)	0.42	
BCL2A1			0.3
High	0.64 (0.34–1.21)	0.17	
Low	1.02 (0.6–1.72)	0.94	
ANGPT1			0.18
High	1.16 (0.69–1.95)	0.59	
Low	0.63 (0.33–1.22)	0.17	
LIFR			0.88
High	0.89 (0.5–1.6)	0.7	
Low	0.91 (0.52–1.59)	0.75	
IDO1			0.89
High	0.85 (0.46–1.6)	0.62	
Low	0.85 (0.5–1.46)	0.56	
PSMB9			0.74
High	0.73 (0.38–1.41)	0.35	
Low	0.94 (0.55–1.59)	0.81	
LEP			0.07
High	1.21 (0.71–2.07)	0.48	
Low	0.56 (0.3–1.03)	0.06	
STC1			0.31
High	0.7 (0.41–1.2)	0.19	
Low	1.1 (0.6–2.02)	0.75	
VIM			0.45
High	1 (0.56–1.79)	0.99	
Low	0.8 (0.46–1.41)	0.45	
KLRK1			0.46
High	0.58 (0.29–1.15)	0.11	
Low	0.9 (0.54–1.5)	0.69	
PDL1			0.93
High	0.77 (0.39–1.52)	0.45	
Low	0.88 (0.53–1.46)	0.62	
TYMP			0.98
High	0.78 (0.41–1.46)	0.44	
Low	0.85 (0.5–1.45)	0.55	
STAT1			0.4
High	0.72 (0.39–1.33)	0.29	
Low	1.04 (0.61–1.79)	0.88	
NKG7			0.17
High	0.55 (0.29–1.04)	0.06	
Low	1.07 (0.63–1.8)	0.81	

0   0.5   1   1.5   2
<---Capecitabine Better---   ---Observation Better--->